Sheldon Tobe

Hypertension and Nephrology, co-Chair C-CHANGE, ❤️🇨🇦, @Sunnybrook, @CHEP+

[Brendon Neuen @brendonneuen]

Finerenone in CKD - an IPD-meta-analysis of FIND-CKD, FIDELIO-DKD and FIGARO-DKD (INFINITY)

Free open access link to the INFINITY analysis in the Lancet (link expires July 25) https://t.co/ag4H8Xkk5m

[ASN Publications @asnpublications]

PREVENT-CVD better predicts combined cardio-kidney outcomes in CKD than traditional risk scores, according to #ASNCJASN study. Adding albuminuria boosts performance, highlighting its value for integrated cardio-renal risk assessment. https://t.co/Hweipj78xG

[Arunkumar @Arunkr_Dr]

@ERAkidney @VladoPerkovic @HeerspinkHiddo @brendonneuen 🔥 INFINITY pooled analysis (FIDELIODKD + FIGARODKD + FINDCKD)
Finerenone: ✅ Kidney outcome HR 0.76 ✅ HF hospitalization HR 0.78 ✅ CV death HR 0.82 ✅ All-cause mortality HR 0.88

One of the strongest cardiorenal datasets yet for CKD across diabetic + non-DM populations #ERA26

[Ahmed Bennis MD 🫀 @drbennisahmed]

NEW in The Lancet (BPLTTC): Lowering systolic BP by 5 mmHg reduces major CV events across all stages of CKD — including Stage 4–5.

Benefit is consistent regardless of CKD status or stage. BP lowering should not be withheld in CKD patients.

#Cardiology #Nephrology

[Ahmed Bennis MD 🫀 @drbennisahmed]

The main finding was simple: a 5 mmHg reduction in systolic blood pressure reduced major cardiovascular events by about 9-10%, with virtually identical relative benefits in patients with and without CKD

Across all CKD stages, including stages 4-5

[Ahmed Bennis MD 🫀 @drbennisahmed]

Regenerating kidneys with your own cells

Rilparencel: autologous kidney cell therapy derived from the patient’s own biopsy, injected directly into both kidneys.

Bilateral injection slowed a rapidly declining eGFR by ~4.5 mL/min/yr. In DKD, that’s clinically meaningful

[NEJM @NEJM]

Original Article: Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection (phase 3 B-Well 1 and B-Well 2 trials) https://t.co/GASbcV9FME

Editorial: A Major Step toward a Cure for Hepatitis B Infection https://t.co/O4kF4cGuuU

#EASL | @EASLnews

[Ahmed Bennis MD 🫀 @drbennisahmed]

MRAs in 2026: far beyond HFrEF.
From spironolactone (RALES, TOPCAT) to eplerenone (EMPHASIS, EPHESUS) to finerenone — the nsMRA reshaping the landscape across HFpEF, HFmrEF, CKD & diabetes.
The heart-kidney axis is the new frontier. 🔬

[KIReports @KIReports]

Randomized Clinical Trial of the Effects of #Vicadrostat #Empagliflozin by #CKD Severity/Hypertension Status

#VisualAbstract by @krishnadoctor1

https://t.co/kNet4MoGkO

[Sheldon Tobe @sheldon_tobe]

Higher age adjusted mortality rates from hypertension is not due to coding. New Canadian data show that once excellent BP control rates are falling. Are BP control rates across the US also falling as an explanation for this worrisome finding?
https://t.co/DjXZjxoGoL

[Sheldon Tobe @sheldon_tobe]

More evidence of the additional benefit of achieving full GDMT for HFrEF, from an observational data set.

[Ahmed Bennis MD 🫀 @drbennisahmed]

🧵 Quadruple GDMT in HFrEF saves years of life — but we’re still falling dangerously short. New data from 20,651 patients 👇

📊 GWTG-HF Registry | N=20,651 patients ≥65 years hospitalized for HFrEF | Linked to Medicare Claims

Greene SJ et al. Eur J Heart Fail. 2026)

[Sheldon Tobe @sheldon_tobe]

Cold induced hypertension adds a circ-annual layer to chronobiology where colder temperatures lead to physiological changes raising blood pressure. I see this every winter in the dialysis unit in many patients, resolving in the Spring and Summer.

[Hypertension @HyperAHA]

REVIEW: Cold-Induced Hypertension as Life-Environment Disease in Winter: Focus on Data From Japan

https://t.co/5HKuNbZUpX

[Ahmed Bennis MD 🫀 @drbennisahmed]

Does digoxin modify the benefit of heart failure therapies?
A subgroup analysis across 4 landmark HFrEF trials gives a clear answer 🧵

The 4 pillars of HFrEF therapy (MRA, ARNI, SGLT2i) retain their efficacy regardless of background digoxin use.

No meaningful interaction

[Sheldon Tobe @sheldon_tobe]

Important. Cuffless monitors are still not recommended for clinical use. They have tremendous potential, but we have to wait.

[European Society of Cardiology Journals @ESC_Journals]

New in #EJPC: Cuffless Blood Pressure Monitoring Devices: Technical Foundations and Clinical Implications: Scientific Statement of the European Society of Cardiology (ESC) Working Group on e-Cardiology, the ESC Council on Hypertension, and the European Association of Preventive Cardiology of the ESC
https://t.co/9sFxL5OtLg

@EJPCEiC @AboyansV @SilCastelletti @PTBuketAkinci @PeroneFrancesco @SMosteoru @TimKambic

[Heart_BMJ @Heart_BMJ]

Natural history of asymptomatic moderate or severe aortic regurgitation: a systematic review and meta-analysis

Please read the article and enjoy an in-depth interview between @jhfrudd and the first author, Dr Jwan Naser from The Mayo Clinic in Rochester, Minnesota, USA

Paper: https://t.co/fxWs0bkEiv

Interview: https://t.co/ZGhyrExOAf

[Sheldon Tobe @sheldon_tobe]

Important commentary on the remaining CV risk in CKD despite advanced therapies. The best treatment is still prevention. And prevention requires early screening for nephropathy, while the eGFR is still normal.

[AJKD @AJKDonline]

NEW Commentary by Bertram Pitt and Michael Holinstat on the #AJKDBlog:

A Decade of Progress: Reducing Cardiovascular Morbidity in Chronic Kidney Disease

https://t.co/GQMCQKcL53

[Gabriel Gregorio Mendez Benitez @gabolino43]

Kidney disease and heart failure: recent advances and current challenges: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference - Kidney International https://t.co/WcxEHSBYzI

[Gunnar Henrik Heine @gunnar_heine]

Obesity in CKD: Core Curriculum 2026
https://t.co/fA8MBqCpVw

[Ahmed Bennis MD 🫀 @drbennisahmed]

Efficacy and Safety of Simultaneous Initiation of SGLT2 Inhibitors and Mineralocorticoid Receptor Antagonists in Patients With CKF or HF

simultaneous initiation of an SGLT2 inhibitor and an MRA produced greater reductions in albuminuria

https://t.co/i6sVTuAqgr

[JAMA Cardiology @JAMACardio]

Premature menopause (age <40 years) was associated with a 40% higher lifetime risk of #CoronaryHeartDisease in both Black and White women, supporting its use as a risk-enhancing factor in preventive care. https://t.co/CEoV8jFMU9